Sanofi-Aventis bid for Genzyme gets really hostile
This article was originally published in Scrip
Sanofi-Aventis's hostile bid for Genzyme is in danger of descending into a French farce. Two days after Sanofi-Aventis decided to take its bid directly to shareholders, Genzyme filed with the SEC all its interactions relating to the approach in a bid to explain why it is calling on shareholders to reject the French bid. Controversially, Genzyme claims that Sanofi-Aventis may be willing to pay up to $80 a share, while the French company denies this and reiterates its $69 a share offer.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.